Dear Good People,
Ladies and Gentlemen, maybe the Yale ones who found the ovarian stem cells should have consulted with this other medical research team from South Dakota while they were all in San Diego...why do men so rarely really listen to each other or me? lol I am such a grim granny, but I have told them before Mifepristone (Mifeprex) would work just like these other guys said at the same AACR conference in this AACR article I saw about new and old drugs in the pipeline. I have added the specific study below...it was at the very bottom of the article, maybe they just didn't look that far...or is it the old eastern medical school versa the western medical school type of competition? hehehe
Why isn't anyone smart enough to give Mifepristone a second chance in human clinical cancer trials for lymphoma too inspite of the bad publicity surrounding it? Will we have to wait twenty-five years? Wasn't that how long it took us to get over the bad media hype about thalidomide babies? Can't they recognize the biochemical and molecular similarities between how Mifepristone(
GBYAY Anne Breen
Contact: Staci Vernick Goldberg
Staci.goldberg@
267-646-0616
American Association for Cancer Research
Drugs in the pipeline: new therapies that could change treatment strategies
SAN DIEGO – New drug compounds, and old ones put to new use, offer doctors and patients new hope for treating and preventing cancer. Studies presented at the 2008 Annual Meeting of the American Association for Cancer Research, April 12-16, show promise and progress against brain, colorectal, rectal and ovarian cancers and lymphoma.
(I found one particular new cell culture study fascinating, because I currently take 200 mg daily of Mifepristone (Mifeprex) since February 2005 to stop my meningioma (a tumor in the cells of the lining of the brain, which are quite similar in cell origin to the cells in the lining the uterus) ...instead of the standard 5 or 6 weeks of IMRT radiation treatment.
GBYAY Anne Breen)
Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment: Abstract 1210
Researchers from the Sanford School of Medicine at The University of South Dakota have demonstrated that mifepristone prevents regrowth of ovarian cancer cells that survive standard chemotherapy.
"Utilizing a cell culture system, our work provides evidence that giving mifepristone between courses of cisplatin has the potential to improve treatment success," said Carlos M. Telleria, Ph.D., the study's senior author and assistant professor of biomedical sciences at the university.
The regrowth of cancer cells between chemotherapy cycles is a major treatment challenge, Telleria says. One strategy to prevent regrowth is the use of drugs like mifepristone, which has been shown in separate studies to prevent cancer cells from multiplying.
Telleria and colleagues observed whether mifepristone would prevent ovarian cancer regrowth if administered with cisplatin. Ovarian cancer cells in culture were treated with cisplatin at 20 µM for one hour every 12 days for 36 days. Researchers assessed the number and viability of cancer cells, and how likely they were to reproduce, every four days.
Cisplatin killed the majority of cancer cells, but those that remained were able to reproduce. However, when mifepristone was added at a dose of 5, 10 or 20 µM the cells, and their ability to reproduce, decreased.
The larger the dose of mifepristone the stronger the effect; at the 20 µM dose, the cultures contained no cancerous cells to test by day 12 of the study.
GBYAY Anne McGinnis Breen
See my smiley face winking at you? &;>)
Keep your faith, cherish your reason, treasure your mind, hold to your own good purposes...and be not afraid.
If you would like to visit my journal pages to read more about my choice of Mifepristone and other grey matters of great importance to me go to
http://journals.
-----Original Message-----
From: Mary (Ryan) Hamilton <Go_Fitz@holtbiz.
To: StemCells@yahoogrou
Sent: Tue, 22 Apr 2008 10:45 am
Subject: [StemCells] Ovarian cancer identified SC
Ovarian Cancer Stem Cells Identified, Characterized
ScienceDaily (Apr. 18, 2008) — Researchers at Yale School of Medicine
have identified, characterized and cloned ovarian cancer stem cells
and have shown that these stem cells may be the source of ovarian
cancer's recurrence and its resistance to chemotherapy.
------------
----------
See also:
Health & Medicine
Stem Cells
Brain Tumor
Prostate Cancer
Skin Cancer
Cancer
Ovarian Cancer
Reference
Embryonic stem cell
Metastasis
Stem cell treatments
Nanomedicine
"These results bring us closer to more effective and targeted
treatment for epithelial ovarian cancer, one of the most lethal forms
of cancer," said Gil Mor, M.D., associate professor in the Department
of Obstetrics, Gynecology & Reproductive Sciences at Yale School of
Medicine.
Mor presented his findings recently at the annual meeting of the
American Association for Cancer Research (AACR) Meeting in San Diego,
California.
Cancerous tumors are made up of cells that are both cancerous and non-
cancerous. Within cancerous cells, there is a further subclass
referred to as cancer stem cells, which can replicate indefinitely.
"Present chemotherapy modalities eliminate the bulk of the tumor
cells, but cannot eliminate a core of these cancer stem cells that
have a high capacity for renewal," said Mor, who is also a member of
the Yale Cancer Center. "Identification of these cells, as we have
done here, is the first step in the development of therapeutic
modalities."
Mor and colleagues isolated cells from 80 human samples of either
peritoneal fluid or solid tumors. The cancer stem cells that were
identified were positive for traditional cancer stem cell markers
including CD44 and MyD88. These cells also showed a high capacity for
repair and self-renewal.
The isolated cells formed tumors 100 percent of the time. Within
those tumors, 10 percent of the cells were positive for cancer stem
cell marker CD44, while 90 percent were CD44 negative.
Mor and his team were able to isolate and clone the ovarian cancer
stem cells. They found that these cells were highly resistant to
conventional chemotherapy while the non-cancer stem cells responded
to treatment. "Isolating and cloning these cells will lead to
development of new treatments to target and eliminate the cancer stem
cells and hopefully prevent recurrence," said Mor.
Adapted from materials provided by Yale University.
Need to cite this story in your essay, paper, or report? Use one of
the following formats:
APA
MLA Yale University (2008, April 18). Ovarian Cancer Stem Cells
Identified, Characterized. ScienceDaily. Retrieved April 22, 2008,
from http://www.scienced
http://www.scienced
[Non-text portions of this message have been removed]
��������������������������������������������
��������������������������������������������
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
��������������������������������������������
��������������������������������������������
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment